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Abstract: Since nonprofits use third-party funds for their activities, they are often perceived as
resource managers or spending units, instead of being considered as social wealth generating entities.
The aim of this study is to help to overcome this myopic perception by showing how the invisible
wealth generated by these organizations can be made visible. We use the SROI methodology to
do so, by identifying stakeholders, outcomes (tangible, intangible) and social impacts in a drug
addiction treatment centre. The results show that social impact in monetary terms exceeds that of the
inputs used, confirming the idea that addiction-based nonprofits are social wealth generating units.
The conclusion drawn is that social impact measurement should be widely used as a management
tool and a mechanism for reinforcing the social image of nonprofits.
Keywords: nonprofits; social impact measurement; social value; SROI
1. Introduction
Currently, it seems accepted that sustainability is more related to the quality of acting with the
purpose of generating a positive and significant impact in critical and relevant areas for society and
the planet, rather than implementing complementary actions to minimize the negative impacts that
leave the actions of organizations [1,2]. This way of understanding sustainability is equally associated
with the identification, measurement and disclosure of economic, social and environmental impacts
(triple bottom line), but it relies even more on social and environmental issues to measure the total
cost of doing business and activities. In this new way of acting, there are traditional organizational
models, such as nonprofits, social economy entities and charities, along with new hybrid organizations
such as social enterprises [1] that are better placed to go that way due to the primacy of their social
mission. Nonprofit, social economy or Third Sector entities are different terms used to designate related
concepts [3,4]. All of them are entities that seek to alleviate the deficiencies of the two traditional
institutional sectors, private and public, carrying out activities for the development and sustainability
of society [5,6]. This means that these organizations not only offset the negative impacts, but also create
positive and meaningful impacts. Without them, the individual and collective needs of communities
would be impossible to meet, so they play a key role in creating more equitable and prosperous
communities. However, much of this role, at both the macro and the micro level, remains undercover
and undervalued due to the methodological constraints of impact measurement. Largely, this problem
has to do with the difficulty of assessing the impacts associated with intangible social costs.
At the meso- and microeconomic level, failure to consider intangible social costs can cause
problems of identity and credibility for nonprofits and charities. Often, what cannot be measured
remains unseen; it effectively does not exist and is not appreciated. Many of these organizations thus
see how a large part of their efforts (e.g., helping drug-dependent people and their family and social
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circle regain quality of life and achieve social reintegration) remain hidden. The fact that they are
rendered invisible reinforces the widely-held view of nonprofits as merely administrative entities [7]
or simple consumers of resources [8], when they should be seen more as social cost-saving units [9],
or even generators of social benefits [10,11]. Along with the abovementioned perception, information
asymmetry also plays a role, whereby the providers of financial resources are recognized above other
stakeholders (volunteers, professionals, beneficiaries, society as a whole [12]).
Consequently, we believe that this represents a clear challenge facing these organizations: publicly
promoting an image of themselves as generators of social wealth, in order to boost their credibility
and strengthen their identity. In this regard, the aim of this paper is to help affirm this image of said
organizations (specifically those specializing in interventions in drug addiction and other addictive
behaviours) by quantifying the social impact they generate. In order to do so, we offer an in-depth
examination of SROI (Social Return on Investment) methodology and highlight its applicability for
measuring the different social impacts (direct, indirect and intangible) typical of organizations in
this field.
SROI is based on a cost-benefit approach that involves the active participation of the stakeholders
in the process of identifying the relationships between inputs and outcomes. The method also includes
a process for monetizing social impacts, whenever possible, which is a positive feature in terms
of the interpretation and comparability of information, primarily from the perspective of a social
investor/donor seeking to allocate funds. The SROI relates the public value generated to the input
invested. Therefore, this method meets the requirements on ‘funding type’ and ‘task programmability
and observability’ that, according to [13], can be applicable to the performance measurement of a
nonprofit as the one we have analyzed, focused on drug rehabilitation.
Several scholars have argued the contribution to the public value as a leading role advocated by
nonprofit organizations, e.g., [14–18]. According to [19] whilst the ultimate value of a private sector
firm’s operations lies in the profit maximization, the ultimate value of a nonprofit organization should
be evaluated by the public value it creates for the community. The value generated by a private firm is
usually summarised into an only performance measure: the profit/return. This measure blends all
the dimensions of the firm’s value chain. Therefore, it would be convenient to show the social value
generated by a nonprofit through a measure that integrates the relevant dimensions of its value chain.
Hills and Sullivan [20] state that the measurement of social value must take into account the quality of
life, well-being, and happiness; the social capital, social cohesion, and social inclusion; the safety and
security; the equality, tackling deprivation, and social exclusion; and the promotion of democracy and
civic engagement. In this study, we argue that SROI blends these items and can be used as a friendly
way to show the social value generated by a nonprofit.
The study focused on analysing the project about toxic addiction carried out by a drug
rehabilitation centre.
The treatment and prevention of addiction continues to represent a major global challenge in the
21st century, as this issue is the axis around which some of society’s main problems currently revolve.
According to the United Nation’s World Drug Report [21], a quarter of a billion people between the ages
of 15 and 64 used at least one drug in 2014, and over 29 million people who use drugs are estimated to
suffer from drug-use disorders. These figures paint a devastating picture of what is left in the wake
of these addictions. Not only has the individual (damage to physical and mental health) but also by
society as a whole felt the negative effects. It is society that has to bear the social costs associated with
premature mortality, lower labour productivity, a greater probability of committing crimes, as well
as the suffering of both the user and their family or social circle caused by this substance abuse [22].
In short, we are facing a problem that concerns both the health and the social and economic welfare
of society. Studies on the social costs of illegal drugs, alcohol and tobacco, both globally and in the
European Union, suggest that these costs are high, consuming a significant share of national GDP [23].
Given the magnitude of the problem, the agent that bears the main responsibility for coordinating
and implementing policies and tackling the social costs of drug addiction is the State [24], though
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it delegates many activities to organizations in the third sector. These organizations are the main
providers of drug treatment programmes, after the public sector [25]. In addition, their closeness to the
population makes them better able to detect emerging needs and carry out diagnostic analyses that
help reformulate strategies, in order to adapt to the changing reality. Such organizations play a key
role in the effectiveness of public policies to tackle drug addiction.
The phenomenon of addiction is a problem that needs to be addressed with both public and
private resources. For politicians, it is very useful to have economic information about social
costs when designing and evaluating prevention and treatment policies. As such, the study of the
macroeconomic impact of addiction, primarily drug use, constitutes a well-established line of research,
with numerous studies addressing the issue through the cost-of-illness (COI) methodology [23].
The fundamental goal of COI studies is to evaluate the economic burden that disease imposes on society
as a whole [23,24,26–29]. When carrying out COI studies, researchers need to recognize, identify, list,
measure and value the costs that a particular disease can generate [30].
In such studies, the associated social costs are classified into three categories: direct, indirect,
and intangible. Direct costs include all the resources and services directly attributed to the disease,
with a distinction being drawn between health-related costs (e.g., hospitalization and medication) and
non-health-related costs (e.g., reintegration into the workforce, judicial procedures). The indirect costs
are those related to the loss of production or productive time associated with the presence of a disease.
Last but not least, intangible costs refer to non-financial welfare losses such as reduced health-related
quality of life due to physical or emotional suffering [24,27,29]. These costs are extremely complex
to quantify because they rarely leave documentary evidence; they are “invisible” [11,31]. That is
why many studies, for the sake of greater objectivity, outline such costs but exclude them from the
calculation and monetization [23,29]. For example, [23] analyse the costs arising from drug addiction
examined in 11 studies of European Union countries, and none of them estimates the intangible costs.
On the other hand, there are studies, albeit fewer, that incorporate these costs into the analysis, with a
careful explanation of the methodology used [24,28].
It is our belief that excluding intangible costs at the macro level is damaging to the nonprofit
sector [32] because it renders a substantial part of the social impact they generate invisible. This is an
impact that, in our case, can be approximated by the social savings associated with the people involved
discontinuing their drug use and regaining their quality of life [11]. Furthermore, information on social
impact is shown to be fundamental when it comes to ensuring greater social trust in this sector [33].
The main contribution of this paper lies, first of all, in the fact that the results help show
organizations dedicated to supporting drug-dependent persons as social cost savers and generators of
social wealth, rather than mere resource managers [7] or organizational units for public expenditure [8].
This helps create a vision of these organizations that underlines their utility to society, their credibility
and the legitimacy of their actions. By doing so, our paper contributes to one of the three directions for
future research proposed by Lee and Nowell [13]: “the role of other less mainstream conceptualizations
of performance measurement (input, public value, etc.) in influencing nonprofit functioning and
effectiveness.” Second, this paper applies the SROI methodology to a field—support for drug-dependent
persons—which has received scant attention both in the theory and in professional practice. While it is
true that SROI is fairly widely used these days, it is not equally widespread in all organizations, nor in
all fields. It is mostly used in nonprofits and in social enterprises, specifically, in the field of labour
market integration and youth groups [34]. Lastly, unlike most of the SROI analyses conducted, which
focus primarily on the individual beneficiary, this paper extends the concept of stakeholders to include
family members, volunteers and professionals who provide their services in the centre, in an attempt
to more fully capture the social impact.
The rest of the paper is structured as follows. The following section examines the role played by
support organizations for drug-dependent persons and Section 3 shows the methodology followed to
evaluate the impact, detailing the method used (SROI), the context under analysis (a charity dedicated
to treatment for drug dependence), and the outcome variables identified. Section 4 presents the main
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results whose discussion has been incorporated in Section 5. Finally, Section 6 outlines the conclusions
of the analysis.
2. The Role of Drug Addiction-Based Nonprofits and Charities in Providing Social Services and
their Contribution to the Economy
Generally speaking, the mission of organizations dealing with drug dependence is to improve
the quality of life and promote the autonomy of people at risk of exclusion, and facilitate their
social integration. Through a wide range of activities and therapies (psychological, sports-based,
socio-educational, vocational training, etc.), they facilitate the acquisition of general skills, abilities and
competencies so that drug-dependent persons can handle their lives constructively and autonomously.
When people decide to check themselves in to a treatment centre to start the drug rehabilitation
process, the discontinuation of drug use gives rise to a number of different effects, such as an
increase in personal wellbeing associated with the development of skills, abilities and competencies
(empowerment, self-control, self-esteem, etc.). This triggers a chain of social cost savings and even
creates benefits, since the positive effects outweigh those costs and the cost of providing the services.
Table 1 provides a summary of these savings.
Table 1. Estimated savings for society stemming from treatment at a drug rehabilitation centre.
Costs of Drug Dependence
Before













Number of HIV/AIDS outpatient care
Resulting from drug-use treatment.
In the healthcare sphere:
Reduction in hospital admissions, primary care
Discontinuation of drug use
Law enforcement and criminal justice costs
In the criminal justice sphere:
Fewer trials
Fewer prison sentences
Other costs (e.g., property destruction, fire loss,
fire prevention)
In the public administration sphere:
Better resource distribution (fewer resources










Lost employment or productivity
In the labour market sphere:
Less job insecurity
Social and labour market reintegration during
the final stages of treatment (improvement in
labour productivity)









Deterioration of quality of life of both the
individual and the family due to the associated
physical and emotional suffering
In the personal, family and social sphere:
Recovery in terms of mental health and quality
of life needed to create improvements in the
other spheres
Source: Own elaboration based on [11,23,29,31].
The different types of social costs caused by illegal drug use have been appropriately identified
and classified (into direct, indirect and intangible costs) in numerous studies [24,29,31]. While it is
certainly true that this classification is not entirely free of the problems associated with identifying
and measuring the different cost items, the social cost elements that are presented in Table 1 are
generally accepted.
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Stopping drug use through the monitoring of a drug treatment programme brings with it numerous
savings, since it involves a reduction in, if not an end to, many of these costs. Resources are thus freed
up for other social purposes. The main savings include:
1. Savings in the healthcare sphere: drug treatment programmes put a stop to the hospital admissions
resulting from drug use (primary care visits, medicines, diagnostic tests . . . ), while also entailing
a reduction in the demand for drugs from people who benefit from the treatment (in Spain, for
example, the hospital cost per person stemming from drug addiction is €399, while primary
care visits related to drugs cost an average of €24.24 per visit [29]). This means they have more
disposable income to devote to the consumption of other goods that contribute to generating
general wealth. Said resources can, in part, be subject to social redistribution through the
applicable taxes—something that does not happen with the money spent on illegal drugs, which
is retained and hidden by mafias.
2. Savings in the employment sphere: abusive and/or habitual drug use is directly associated
with greater job insecurity, repeated absences, sick leave, etc. In response to this, the treatment,
mostly in the final phases, puts increased emphasis on the processes of social and labour market
reintegration for the people undergoing treatment [11]. In addition, treatment programmes for
drug dependence, along with other educational and therapeutic activities, encourage training
and active job searches.
3. Savings in the criminal justice field: given the relationship between drug addiction and crime,
every day spent in treatment translates to a reduction in crimes that would have gone to trial
and even, on occasion, would have resulted in another prison sentence—at least relative to the
rate and duration occurring before treatment. The savings in this area are threefold: fewer trials,
fewer custodial sentences and the savings resulting from people staying out of prison as they do
not commit any further crimes.
4. Savings in intangible costs: the therapeutic support received on being admitted to a specialist
organization allows the beneficiaries and their families to initiate processes aimed at breaking
the dynamics of pain and suffering in which they are immersed. This provides them with the
necessary tools at a personal level (i.e., self-control, self-esteem, etc.) to successfully complete the
rehabilitation process and achieve social reintegration. Without these personal achievements,
the anticipated savings in the other areas are vulnerable and prevention policies are doomed to
fail. Fundamental to the process are health monitoring and professional work, as well as the
psychological, socio-educational, sports-based and vocational training therapy carried out by
these organizations. Each step forward a person makes in their rehabilitation process translates
into improvements in their quality of life, as well as in their personal and family wellbeing,
which help prepare them to tackle subsequent stages. These achievements are essential and lie at
the heart of these organizations. Therefore, this process of recovery from a deteriorated quality
of life, both personal and family, must be made visible qualitatively or quantitatively. From a
quantitative point of view, specific measurement instruments have been developed to evaluate
drug-dependent persons’ perceived quality of life, see [35]: Qol-DA (Quality of Life Scale for Drug
Addicts); IDUQoL (Injection Drug User Quality of Life Scale); TECVASP—Test for Evaluating
the Quality of Life in Psychoactive Substance Addicts; HRQOLDA Test (Health-Related Quality
of Life for Drug Abusers Test, GENCAT Scale. Additionally, also applicable are the measures
of quality of life associated with medical pathologies, such as the Quality-Adjusted Life-Year
(QALY), which is widely used in Health Economics.
Unlike cost analysis, which has traditionally been approached from a macroeconomic perspective
in the literature, this paper aims to estimate savings and impacts from a meso- and microeconomic
perspective, given that the range of specific activities provided by the organizations varies widely, as
do the achievements. The rest of the study focuses on this analysis of the impact generated.
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3. Methodology
This study uses the SROI method to measure the social impacts generated by the operations of
a centre dedicated to treating people with drug addiction problems: the Los Granados therapeutic
community (LGTC hereafter), in Castellón, Spain. SROI is a method used to account for social value,
implemented mainly by charities and nonprofits [34]. One of the characteristics of SROI that sets
it apart from other methodologies is that it attempts to monetize the social impact [36], which is a
positive feature in terms of interpretation and comparability of information; however, it is an aspect
that has not been free of controversy [34]. SROI [37–40] is based on a cost-benefit approach but it
incorporates a distinctive feature that represents the cornerstone of the process [41]: the participation
of stakeholders in the process of identifying the relationships between inputs and outcomes, and in
determining positive impacts. This offers a much more comprehensive picture of the social impact
(For a comprehensive picture of the path to follow for the application SROI and the monetization
procedure, see [42]).
3.1. Scope, Approach and Identification of Stakeholders
The first step to take when performing an SROI analysis is to explicitly narrow down and delimit
what is going to be measured. In our case, SROI is to be used on the LGTC, managed by the NGO
PATIM, a nonprofit organization dedicated to the prevention of, counselling and treatment for, and
research into addictions and other behaviours. The present study measures the social impact generated
by the LGTC in 2015; it is therefore a retrospective SROI analysis.
A qualitative methodology was used to collect information, consisting of a series of initial
interviews, which subsequently led to the identification of stakeholders in the organization and the
main changes perceived. Table 2 shows all the stakeholders identified according to their direct or
indirect interest in the programme, indicating those that were eventually excluded from the analysis.
Table 2. Identified stakeholders (included and excluded).
Stakeholders Description Criteria for Inclusion Criteria for Exclusion
Users People admitted to theservice to detox.
People directly linked to
the service.
Main beneficiaries
Family Members Relatives of patients. Indirect beneficiaries. Partial deadweight (1)
Volunteers
People who voluntarily
work in the service,
preparing and running
some of the workshops.
They run workshops.
Professionals People who workin the centre.




Public administration Prison facilities. Cost savings.(3)
Student interns People doing aninternship in the centre.
They do not affect nor are they affected by the
programme itself; they are external to it. They could






as an alternative to being
sent to prison.
No interaction with the programme itself.
Source: Own elaboration. (1) Family members stated that they spent between 6 and 8 hours a day caring for the
individual, but that they did not need to hire anyone specifically to handle this care, nor did they have to request a
reduction in their working hours. (2) The workers of the centre, essential for its operation, could equally provide
their professional services in another organization. (3) When some drug-dependent persons commit minor offences,
such as robberies, the judge may offer to replace their sentence by admission to a detox centre.
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3.2. Outcomes, Measures and Monetary Conversion Factors
The stakeholders selected for inclusion in the analysis reported different changes experienced after
treatment at the centre (see Table 3). For example, in the case of users, the main change identified is the
improvement in their quality of life as a result of acquiring new, healthier habits, the boost to their
self-esteem and self-control, and improvements in social relationships and their health, both physical
and psychological. In the case of public administration, due to the type of collaboration between the
centre and the judicial system, the impacts take the form of savings in prison costs (the information
provided by the programme users did not allow a sufficiently reliable estimation of the savings in
healthcare costs—hospitals and outpatient clinics), and so they have been excluded from the analysis);
specifically, the costs corresponding to those users who would be in prison if they were not in the
community programme.
Table 3 shows the outcomes, the measures and the monetary conversion factors used. Based on
this information, in order to quantify the intangible outcomes, different specific questionnaires were
administered to the same sample of individuals using an “ex-ante/ex-post observation” approach
(as suggested by [43], p. 11).
Table 3. Tangible and intangible outcomes, measures and monetary conversion factors.
Stakeholders Outcomes Type Measures MonetaryConversion Factor




































due to not using
drugs
Tangible Surplus due tonon-use
Average individual
spending per day
on drug use [11]









of one day in
prison ([50], p.137).
Source: Own elaboration.
(a) Improvements in users’ quality of life
The previous literature considers the reduction in the quality of life for users as well as those
closest to them, as a social cost that is both intangible [24,27,29] and invisible [23]. To measure the
improvement in users’ quality of life after treatment at the centre, the GENCAT Scale has been used,
as it is the most appropriate instrument for assessing the individual quality of life of people with drug
dependencies [35].
The GENCAT Scale [44] was developed from the multidimensional model of [51] and it enables
a comprehensive evaluation of quality of life [52]. The scale provides valid and reliable scores for
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the following dimensions: (1) Emotional wellbeing, (2) Physical wellbeing, (3) Material wellbeing, (4)
Self-determination, (5) Personal development, (6) Social inclusion, (7) Interpersonal relationships, and
(8) Rights, as well as an overall quality of life index. The questionnaire was administered to a sample
of 13 individuals, who described their perceptions before and after treatment at the centre. As they
were the same individuals, it was not necessary to use a control sample.
Once quality of life has been measured, the key question is whether it can be valued in monetary
units. Studies show that there is a direct relationship between income and wellbeing [53,54]. In
addition, literature collects a series of methods that can be used to measure the intangible impacts
(some examples can be seen at [38,55–57]). This paper uses the synthetic health indicator, QALY
(Quality-Adjusted Life-Year), an outcome measure that is widely accepted in cost-effectiveness
studies [48,58–61]. The QALY indicator is a health-related measure of quality of life [62] so its value
depends on the pathology or condition under analysis.
In the specific field of drug dependence [63] point to losses per year of dependence and use
are 0.113 for cannabis, 0.184 for benzodiazepines and 0.27 for heroin or multiple drugs. [64] show a
QALY loss of 0.2 for each year that injecting drug users do not participate in methadone maintenance
treatment, and a QALY loss of 0.1 for each year they were in treatment. [65] assign a value of 0.125
QALY to the effect of long-term dependence. Taking all these data into consideration, [46] uses values
of 0.1 for cannabis dependence and 0.2 for dependence on cocaine, heroin or methamphetamines.
The drug-dependent persons undergoing treatment at the LGTC have a diverse drug-use profile. As
such, we decided to take the mean value of the two extremes indicated by [46] that is, a QALY loss of
0.15 caused by drug dependence.
In addition, to compute the cost per QALY, we have chosen the range proposed by [45].
They estimate this cost is between €22,000 and €25,000 (in 2012 euros). We have updated them
to 2015 values, resulting in a cost per QALY of between [€20,291–€25,364]. The year-on-year variation
in per capita GDP has been taken as the updating coefficient. Table 4 shows the main parameters
considered in the monetization process.
(b) Improvement in family members’ emotional wellbeing
In order to quantify and monetize family members’ emotional and social improvements, an
adapted version of the questionnaire for family members from the DAU Foundation study was
used [47]. Questions others than those related to outcomes identified by relatives were excluded.
The questions come from the European Social Survey (ESE), which uses validated questionnaires on
different aspects such as social and personal wellbeing or health. Seven responses were obtained.
This questionnaire also addressed two points in time: before and after treatment [11,43].
As with users’ quality of life, the monetization of the improvement in family members’ emotional
wellbeing was based on QALY. [48] estimate the impact of severe emotional disorders on quality of
life at 0.17 QALYs. However, the information obtained did not justify classifying the family members’
disorder as severe, so, following the correction criteria used by [47], the loss of quality of life suffered
was estimated at only a quarter of that value (that is, 0.25 × 0.17 QALYs = 0.0425 QALYs). For the
cost per QALY, the range estimated by [45] for the Spanish National Health Service was again used
(Table 4).
(c) Improvement in family members’ social relationships
The problem of drug addiction has a negative impact on social relationships, both those of the
users themselves and those of the family caregivers [67]. The restoration of social relationships was
measured with the information obtained from the questionnaire indicated in Table 3.
The improvement in family members’ social relationships has also been monetized on the basis of
QALY. To that end, it is assumed that the individual’s quality of life is a multidimensional concept and
it is necessary to approximate the relative weight of social relationships in said quality. The number
of dimensions considered varies according to the authors (see for example [67–69]). The World
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Health Organization (see [70]) identifies six distinct dimensions, four of which are related to health
(Health-Related Quality of Life: Physical health (HRQoL), Psychological health (HRQoL), Level of
independence (HRQoL), Social relationships (HRQoL), Environment and Personal values and beliefs).
This last study has been taken as a reference; it does not provide information on the relative weight
of each component but taking into account the fact that one of the four health-related dimensions
corresponds to social relationships, this dimension has been assigned a weight of 0.25.
Table 4. Method for monetizing the impacts for different stakeholders.
Impact Monetization Method Quantity(*) Quality(**)
Improvement in quality
of life (users)




Vallejo et al. (2017)
40 (1)
QLI increase:
from 83.12 to 115.69
(minimum and maximum








Vallejo et al. (2017)
40
Average increase in the
emotional wellbeing
indicator from 0.257 to 0.4








Vallejo et al. (2017)
40
Average increase in the
social relationships
indicator
from 0.529 to 0.714












income for one year by




Cost of an internship
credit in an official








6 ECTS credits (3)
Cost savings on prison
facilities (4)




Estimated number of days
spent in prison: 96 (6)
(*) Quantity: individuals affected by change. (**) Quality: the extent to which things change for them. Source: Own
elaboration. (1) The centre treats 40 people a year. (2) Number of volunteers in the centre every year. (3) 6 ECTS:
internship credits of an official master’s degree in the subject area. (4) The users’ hospital and outpatient costs have
been excluded as very little related information is collected and it is not very reliable. (5) PATIM carried out a total
of 20 expert assessments in 2015, resulting in 17 admissions to the therapeutic community. (6) At a conservative
estimate, it has been considered that admission to the centre is equivalent to serving a weekend detention sentence
for one year, which means a total of 96 days.
Furthermore, it should be noted that family members’ social relationships were not completely
deteriorated prior to the user’s admission to the centre, so the QALY needs to be adjusted. The value
of the indicator before and after the user’s treatment at the centre was 0.529 and 0.714, respectively,
showing an improvement in these relationships quantified at 0.185. This weighting is used to assign a
monetary value to QALY in the context of the deterioration of family-caregivers’ social relationships.
In short, this approach entails, indirectly, assigning social relationships 0.04625 QALY (0.25 × 0.185)
(Table 3).
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(d) Increase in the family unit’s disposable income due to not using drugs
Another identified impact affecting the family unit (users and family members together) is the
increase in disposable income as a result of the discontinuation of drug use (Table 3). The money
previously spent on drugs, retained by drug trafficking networks, is freed up for other purposes
and generates an increase in purchasing power within the family unit [11]. This greater disposable
income has a net marginal effect on social wealth. The marginal propensity to consume indicates the
proportion of each additional euro saved that is spent on consumption; the benefit to society can thus
be monetized.
This impact has therefore been monetized on the basis of the estimated average individual daily
expenditure on drug use, calculated at €26.86 (see [11]). The 2014 marginal propensity to consume has
been applied [66] (Table 4).
(e) Volunteers’ professional development and acquisition of professional experience
The work that volunteers do in the project enables them to acquire a set of abilities, skills and
competencies that broaden their range of professional opportunities. This work is equivalent to that
carried out in professional internships. Therefore, when monetizing this impact, we use the cost of a
master’s degree internship credit in the relevant subject area as an indicator (see Table 4).
(f) Savings in judicial costs
Under the Spanish legal system, when people with substance addictions commit minor offences,
such as robberies, the judge can impose an alternative sentence whereby offenders are sent to a drug
treatment centre (as the LGTC) to undergo a certain treatment programme. Consequently, users
admitted to the programme for this reason, in line with the literature, represent a saving that is at
least equivalent to the cost of a custodial sentence. Without accounting for the rest of the direct social
costs established by the literature, such as police costs, judicial costs or property damage [23,27,29], the
savings generated have been calculated on the basis of the average daily cost of a prison inmate [11,49].
The monetary conversion factor was taken from the Council of Europe’s SPACE I Report ([50] p. 137)
with 2011 data (€65 per person per day) and the CPI was used to update it to 2015 values (€65.78 per
person per day, Table 4).
4. Results
4.1. Monetized Impacts
The results suggest that undergoing treatment in the therapeutic community has had a positive
impact on people with addiction problems. On average, users’ quality of life index increased by 32.07
after undergoing treatment (from 83.62 to 115.69). The minimum and maximum values of the quality
of life index are, respectively, 52 and 138. The economic valuation of this improvement, for the 40
individuals who were treated at the LGTC (Table 3) is based on a value of 0.15 QALY per year of
treatment, with the cost per QALY lying within the range [€20,291–€25,364]. On the basis of these data,
the monetary value of the annual contribution that the LGTC makes to improve the quality of life of its
users ranges between €120,000 and €152,000 (Table 5).
Family members have also experienced improvements stemming from the activity carried out
in the LGTC. On average, family members’ emotional wellbeing improves by 0.143 with the user’s
treatment (from 0.257 to 0.4), that is, by 14.3%. On the other hand, social relationships go from a value
of 0.529 to 0.714 (out of a maximum of 1), which also indicates an improvement. To monetize the
improvements in family members’ emotional wellbeing and social relationships, the values of 0.0425
QALY and 0.04625 QALY per year of treatment were applied, respectively, with the same cost per
QALY and number of individuals mentioned above. The resulting amounts are shown in Table 5.
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Table 5. Monetized impacts.
Stakeholders Impact
Tangible Intangible Total
































358,332.80 194,891.77 243,337.48 553,224.57 601,670.28
Source: Own elaboration.
Table 5 also shows the monetary value of the increase in disposable income in the family
unit (€250,979.84), the monetized value of abilities, skills and competencies acquired by volunteers
(€1,108.80) and the judicial cost savings brought about by the LGTC (€107,352.96); all these amounts
were calculated according to the abovementioned criteria (Table 4).
4.2. SROI Calculation
In order to calculate social return, as well as determining the impacts detailed in the previous
section, it is necessary to know the total resources the organization has used to fund the activities that
have had an impact. In 2015, PATIM allocated a total of €190,838.10 to the LGTC.
As can be seen in Table 5, the total value of the impacts corresponding to tangible elements
is €358,332.80 and the SROI ratio is 1.88; that is, every euro invested in the programme run by the
centre generates a tangible return of €1.88 (see Table 6). However, SROI not only takes into account
these impacts on tangible elements, but also considers the intangibles. Specifically, the analysis yields
an SROI of between €2.9 and €3.15 (see Table 6). This means that for every euro invested in the
LGTC, the centre generates a minimum impact of €2.9. In other words, taking into account tangible
savings, intangible savings and social benefits, the wealth that the organization gives back to society is
conservatively valued at €2.9 for each euro it manages. This is an entity that generates social wealth by
managing funds received from different sources (public and private).
Table 6. Calculated returns.
Tangible Intangible SROI











Inputs 190,838.10 190,838.10 190,838.10 190,838.10 190,838.10
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It should be underlined that the results presented here correspond to one year of activity. Given that
the LGTC operates continuously, the social return is ongoing.
5. Discussion
There are several articles that present extensive literature reviews on this topic including
peer-reviewed articles and gray literature ranging between 2005 and 2016, but none collect any
work specifically related to drug dependence or focused on addiction treatment [43,71]. While this is a
recognized limitation, attempts were made to detect any academic work on these issues so far, but
without success. There are probably unpublished SROI studies but not in the public domain. Anyway,
beyond specific comparisons, in general terms, the results of the present paper are aligned with those
achieved by other authors. Our study suggests that addiction-based nonprofits and charities are not
only managers of third-party resources [7] but (social) wealth-generating entities as well. While the
single case aspect of this study can be considered a constraint for generalizability, literature gives us a
bridge to do it by presenting a range of SROI studies reporting positive SROI ratios across healthcare
settings (see [43]). Even though they vary over a wide range of values, all of them are positive and
support the social wealth-generating approach we propose for nonprofits.
Another field that allows a comparison of the achieved results is the monetization method. We
have not used any stated preference method, as [72] do. As [73], we use revealed preference techniques
for those outcomes where market values can be determined. This allows us to overcome the subjectivity
of the stated preference methods where the stakeholders are directly asked about their perception on
monetary value of goods and services.
For the monetization of the quality of life, we have used an approach similar to that used by [74].
These authors quantify the individual’s subjective wellbeing through an estimation of the level of
life satisfaction. We also use the concept of subjective wellbeing, but we support our monetization
approach on QALY, as other authors have done.
Our SROI estimates are cautious, since the underlying assumptions when monetizing the impact
on quality of life and disposable income have been conservative. Numerous authors have estimated
the cost per QALY. According to [75], it is estimated at €40,000 on the context of work accidents
and work-related ill-health. [76] establishes a value of $116,500 in the field of tobacco-related health
problems. [47] estimates the cost at €49,500 in relation to traffic accidents. There is a wide range of values
as has already been noted in some studies [77,78], because the QALY value depends on the context of
the patients who are taken as a reference. In light of the above, we have considered more appropriate
to use a range for the QALY value rather than a single monetary value. We have also monetized both
the improvement in the user’s quality of life and in family members’ emotional wellbeing using the
cost per QALY cautious approach suggested by [45]. Moreover, for the monetization of disposable
income, we have used also a conservative estimate: the average of the daily expenditure on drug use.
The studies carried out indicate that cocaine is the most expensive substance in the market [79] and
that the region where the centre under analysis is located (the Valencian Community) reports even
higher levels of cocaine use than the region where the estimation was made (Balearic Islands) [80,81].
For reasons of homogeneity and consistency with the health sphere, we used QALY to monetize
all indicators related with health recovering, including social relationships. The literature has primarily
used the shadow pricing method to monetize social relationships. An interesting study in this respect
is that of [55], who estimates the annual monetary value of social relationships in the UK at £85,000
(€108,000). This value is higher than most of the monetary values we have detected in the literature.
It does not seem to make sense since the latter estimate takes a comprehensive view of quality of life, in
all its dimensions (social relationships is one of them). The inconsistency arises from the use of different
monetization methods: shadow pricing in the case of social relationships, and QALY for quality of life
and emotional wellbeing. This underlines one of the main challenges in the valuation of intangibles:
extreme care should be taken when choosing monetary conversion factors and aggregating the results.
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The monetization methods for different impacts must be consistent. Otherwise, the simple aggregation
of results is not feasible.
6. Conclusions
Nonprofits, for the primacy of their social mission, have to show the global vision about their
activities, so they must calculate and show their social and economic results. Describing and measuring
the social impacts that these organizations bring to society is a difficult work and it is a real challenge to
have criteria and instruments that make easier this task. Thus far, academics have been slow to adopt
SROI methodology in health and social care, and there is little evidence, mainly focused on social and
labor integration, the healthcare sector, blood donor associations, functional diversity assistance or
emergency shelter for minors. To fill the gap, this study contributes to increase the evidence on the
development of the SROI methodology: firstly, by applying the methodology to a new unexplored
field, a drug addiction treatment center, and, secondly, by providing a range of concrete measurement
tools and widely tested monetary conversion factors to assess the specific impact on the community.
It is easy to appreciate the results and impacts of the action of a nonprofit organization on patients
and their families, such as those that help overcome drug addiction, especially when we are the direct
beneficiaries. However, it is harder to recognize the full impact that these entities produce indirectly in
society as a whole. This study tries to shed light on this subject, since it makes visible the invisible
wealth created by nonprofit and hybrid organizations (social enterprises, social economy entities),
a key element to understand both their organizational sustainability (we show that they are wealth
generating units, not expenditure centers), and its contribution to sustainable development (we show
the process of generating positive impacts).
The results obtained show the importance of measures to quantify the social impact generated
by socially-beneficial organizations. If, as is standard practice, their results are valued from a purely
economic and financial perspective, it may seem that they do not generate enough income to cover
their expenses, requiring subsidies and grants to survive. These types of restricted and myopic
interpretations tend to paint nonprofit organizations more as consumers or managers of third-party
resources than (social) wealth-generating entities.
The calculations for the LGTC have demonstrated the social wealth-generating role of the
organizations dedicated to caring for drug-dependent persons. Due to the difficulties in measuring this
wealth, it tends to be relegated to the background, or even rendered invisible. For this reason, the use
of measures aimed at revealing the social wealth generated is recommended. These measures should
come from the organizations themselves, and they must be committed to using information on social
impacts for their internal management and decision-making (the feedback provided by participatory
evaluation instruments such as SROI is a very rich source of data). However, measures should also
come from the public administration, which should incorporate variables that reflect the social impact
into its decision models for the allocation of public resources. Failure to do so would mean that it is
being managed in a myopic, biased and unsustainable way because the social wealth generated, even
if only considered in terms of cost savings, remains undervalued.
The quantification and monetization of intangible outcomes is certainly one of the most widely
criticized aspects of impact assessment. We believe that the difficulties involved in identifying objective
indicators and standardized monetary conversion factors should not be a pretext for dismissing
intangible outcomes altogether. Quite the contrary, it provides an opportunity to examine how
to obtain generally-accepted indicators and standardized monetization methods that reinforce the
comparability of the information. This study shows, for example, that monetary values of intangibles
obtained through different monetization methods should not be aggregated. Therefore, when assigning
a monetary value to the impact of intangibles, only standardized values should be aggregated;
otherwise, the results will be meaningless and will lack transparency. It is necessary to provide
information about criteria, methodologies and calculations in order to allow a proper interpretation of
the data and enable decision-making.
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The single case aspect of this study can be considered a constraint for generalizability. Outputs,
outcomes and key variables will be different for those nonprofits whose activity does not focus on
the addiction problems. Nevertheless, the paper demonstrates that the task of a nonprofit contributes
to the generation of value for the society. Furthermore, this generation can be appreciated through a
measure, the SROI, which integrates all the dimensions of the social value chain. In addition, given
that the SROI framework actively involves all stakeholders, it is a framework for continuous learning
for all of them, especially patients undergoing treatment, who become protagonists of the story of their
own experienced changes.
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